3485-62-9 Usage
Description
Clidinium bromide, also known as 3-hydroxy-1-methylquinuclidinium bromide benzilate (Quarzan), is a white or nearly white, almost odorless, crystalline powder that is optically inactive. It is soluble in water and alcohol but only very slightly soluble in ether and benzene. Clidinium is a gastrointestinal muscarinic receptor antagonist with a Ki value of 3 nM against [3H]quinuclidinyl benzilate binding in rat colonic enterocytes. It is used for the symptomatic treatment of peptic ulcer disease and to help relieve abdominal or stomach spasms or cramps due to colicky abdominal pain, diverticulitis, and irritable bowel syndrome.
Uses
Used in Pharmaceutical Industry:
Clidinium bromide is used as an anticholinergic for its antispasmodic properties, helping to relieve abdominal or stomach spasms and cramps caused by conditions such as colicky abdominal pain, diverticulitis, and irritable bowel syndrome.
Used in Gastroenterology:
Clidinium bromide is used as an anticholinergic for its antispasmodic effects, aiding in the symptomatic treatment of peptic ulcer disease by reducing the muscle contractions in the gastrointestinal tract and alleviating discomfort.
Used in Epilepsy Research:
Clidinium bromide has been studied for its effects on inducing constipation in mice, which in turn leads to serum hyperammonemia and decreases seizure thresholds in a murine pentylenetetrazole-induced epilepsy model. This research could potentially contribute to the understanding of seizure mechanisms and the development of new treatment strategies for epilepsy.
Brand Name:
Quarzan (Roche) is the brand name under which clidinium bromide is marketed.
Originator
Librax,Roche,US,1961
Manufacturing Process
5.12 g of 1-azabicyclo[2.2.2]-3-octanol were refluxed with a suspension of
0.92 g of finely divided sodium in 50 cc of toluene, until most of the sodium
had reacted (about 4 hours). The thus obtained suspension of the white
amorphous alcoholate was cooled with ice, and reacted with 10.16 g of
diphenylchloroacetyl chloride, which was added in form of a solution in
approximately 40 cc of toluene. The mixture was stirred for 1 hour at room
temperature. Small amounts of unreacted sodium were destroyed with
isopropanol, and 120 cc of 1 N hydrochloric acid were then added, The
mixture was refluxed for 1/2 hour, in order to convert the first formed
product, diphenylchloroacetic acid ester of 1-azabicyclo[2.2.2]-3-octanol, into
the corresponding benzilic acid ester.
The toluene phase was separated and discarded. The aqueous phase, together
with a precipitated water- and toluene-insoluble oil, was made alkaline and
extracted repeatedly with chloroform. The chloroform solution was
concentrated in vacuo. The residue was recrystallized from a mixture of
acetone and ether (alternatively, from chloroform and ether), and formed
needles melting at 164° to 165°C. It was identified as 3-benziloyloxy-1-
azabicyclo[2.2.2]octane.
3-Benziloyloxy-1-azabicyclo[2.2.2]octane methobromide was prepared by
adding 20 cc of a 30% solution of methyl bromide in ether to a solution of 2.5
g of 3-benziloyloxy-1-azabicyclo[2.2.2]octane in 20 cc of chloroform. After
standing for 3 hours at room temperature and 15 hours at +5°C, a crystalline
precipitate had formed. This was filtered off and recrystallized from a mixture
of methanol, acetone, and ether; prisms melting at 240° to 241°C.
Therapeutic Function
Anticholinergic, Antiulcer
Clinical Use
This anticholinergic agent is marketed alone and in combinationwith the minor tranquilizer chlordiazepoxide (Librium)in a product known as Librax. The rationale of the combinationfor the treatment of GI complaints is the use of an anxiety-reducing agent together with an anticholinergic agent,based on the recognized contribution of anxiety to the developmentof the diseased condition. It is suggested for pepticulcer, hyperchlorhydria, ulcerative or spastic colon, anxietystates with GI manifestations, nervous stomach, irritable orspastic colon, and others. Clidinium bromide is contraindicatedin glaucoma and other conditions that may be aggravatedby the parasympatholytic action, such as prostatic hypertrophyin elderly men, which could lead to urinary retention.
Check Digit Verification of cas no
The CAS Registry Mumber 3485-62-9 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 3,4,8 and 5 respectively; the second part has 2 digits, 6 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 3485-62:
(6*3)+(5*4)+(4*8)+(3*5)+(2*6)+(1*2)=99
99 % 10 = 9
So 3485-62-9 is a valid CAS Registry Number.
InChI:InChI=1/C22H26NO3.BrH/c1-23-14-12-17(13-15-23)20(16-23)26-21(24)22(25,18-8-4-2-5-9-18)19-10-6-3-7-11-19;/h2-11,17,20,25H,12-16H2,1H3;1H/q+1;
